• In October 2025, NeoGenomics presented new research at the International Society of Liquid Biopsy Annual Congress confirming that its RaDaR ST assay achieves 97% concordance and maintains sensitivity compared to the previous RaDaR 1.0 version for detecting molecular residual disease in solid tumors, along with analytical validation of its new genomic profiling assays and updates on its NextGen MRD research program.
• This research strengthens NeoGenomics' position in liquid biopsy and molecular diagnostics by supporting continuity as technology platforms evolve and expanding coverage across cancer types.
• We’ll now explore how the RaDaR ST assay’s robust clinical validation and expanded research portfolio may influence NeoGenomics’ investment narrative.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

NeoGenomics Investment Narrative Recap

To be optimistic on NeoGenomics as a shareholder, you have to believe in the continuous growth of advanced molecular diagnostics and the company’s ability to convert cutting-edge research, like the RaDaR ST assay’s strong clinical performance, into market share and revenue stability. While the October research results are promising for the company’s liquid biopsy platform, the main short-term catalyst remains execution on broader product launches and revenue growth, whereas the persistence of increasing losses still represents the most acute business risk; the new data does not materially change that risk balance.

Among recent announcements, the July 2025 launch of NEO PanTracer LBx, a therapy-selection genomic profiling test, is particularly relevant. The current RaDaR ST results reinforce the need for NeoGenomics to deliver robust product performance and validate new assays to drive adoption across more cancer types, a critical next step for unlocking the potential of its expanding clinical portfolio and supporting volume-driven revenue acceleration.

In contrast, investors should be aware that losses continue to widen as investment in technology ramps up and...

NeoGenomics' outlook anticipates $893.1 million in revenue and $48.1 million in earnings by 2028. This scenario depends on 9.0% annual revenue growth and a $152.1 million earnings increase from the current level of -$104.0 million.

Uncover how NeoGenomics' forecasts yield a $11.72 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Three retail investors in the Simply Wall St Community value NeoGenomics’ shares between US$10.20 and US$19.00, showing widely varying expectations. Against this backdrop, ongoing losses and market competition remain crucial context for understanding the company’s path forward, so consider a range of views before making up your mind.

Explore 3 other fair value estimates on NeoGenomics - why the stock might be worth just $10.20!

Build Your Own NeoGenomics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your NeoGenomics research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.